Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Lucid Diagnostics ( (LUCD) ) has issued an update.
Lucid Diagnostics reported that in the fourth quarter of 2025 it processed 3,664 EsoGuard tests and generated $1.5 million in EsoGuard revenue, while full-year 2025 revenue reached $4.7 million. For the quarter ended December 31, 2025, operating expenses were $15.5 million and GAAP net loss attributable to common stockholders was $16.3 million, or $0.12 per share, with a non-GAAP adjusted loss of $12.6 million.
The company highlighted a U.S. Department of Veterans Affairs contract that extends EsoGuard access across roughly 170 VA medical centers, with Medicare-aligned pricing and potential exposure to about nine million veterans. Lucid also reported positive real-world data from nearly 12,000 at-risk patients showing a 95% technical success rate for EsoCheck and rapid procedure times, while ending 2025 with $34.7 million in cash and cash equivalents, up from $22.4 million a year earlier, supporting its efforts to deepen health system adoption and advance payer coverage.
The most recent analyst rating on (LUCD) stock is a Buy with a $3.00 price target. To see the full list of analyst forecasts on Lucid Diagnostics stock, see the LUCD Stock Forecast page.
Spark’s Take on LUCD Stock
According to Spark, TipRanks’ AI Analyst, LUCD is a Neutral.
LUCD scores low primarily due to weak financial performance (negative margins, widening losses, rising leverage, and persistent cash burn). Technical indicators also skew bearish (below key moving averages with negative MACD), while the earnings call provides partial support via improved liquidity and encouraging Medicare coverage progress. Valuation offers limited help because losses make P/E less informative and no dividend yield is available.
To see Spark’s full report on LUCD stock, click here.
More about Lucid Diagnostics
Lucid Diagnostics Inc., a subsidiary of PAVmed Inc., is a commercial-stage cancer prevention medical diagnostics company focused on detecting esophageal precancer. Its primary products include the EsoGuard Esophageal DNA Test and the EsoCheck Esophageal Cell Collection Device, targeting at-risk patient populations through health systems, commercial payors and large integrated providers such as the U.S. Department of Veterans Affairs.
The company operates in a competitive diagnostics market where early detection technologies are increasingly important for payors and providers, and it seeks to differentiate through real-world clinical evidence, broader reimbursement and integration into large healthcare networks. Lucid’s strategy emphasizes scaling test volume, converting demand into recognized revenue and securing coverage from both commercial insurers and government programs such as Medicare to support long-term growth.
Average Trading Volume: 1,309,825
Technical Sentiment Signal: Hold
Current Market Cap: $156M
For an in-depth examination of LUCD stock, go to TipRanks’ Overview page.